Global Meningococcal Vaccines

Meningococcal Vaccines Comprehensive Study by Type (Polysaccharide Vaccines, Conjugate Vaccines, Combination Vaccines, Others), Application (Pneumonia, Meningitis, Bacteremia, Others (Arthritis, Conjunctivitis, Urethritis)), Brand (Menactra, Menveo, Nimenrix, Trumenba, Bexsero, Others), Distribution Channel (Pharmacies, Community Clinics, Public Health Agencies, Others (hospital pharmacy, private market etc.)), Age (Infants, Children, Adolescents & Young Adults, Adults) Players and Region - Global Market Outlook to 2030

Meningococcal Vaccines Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Meningococcal Vaccines
Meningococcal vaccine is used to prevent diseases caused due to Neisseria meningitidis, also known as meningococcus, is a Gram-negative bacterium that can cause meningitis and other forms of meningococcal disease such as meningococcemia. Meningococcal vaccines are witnessing a substantial demand in line with a notable rise in their use outside of routine immunization. The growing use of meningococcal vaccines for immunization of special risk groups, including travelers, or military personnel, and for recommended but not-reimbursed immunization, is fueling gains in the market.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The global Meningococcal Vaccines market is fragmented and the leading pharmaceutical companies are working on their research and development team to clear all the clinical trials and get approval from the FDA to launch its vaccines. Analyst at AMA Research estimates that Global Players will contribute the maximum growth to Global Meningococcal Vaccines market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Pfizer Inc. (United States), Novartis AG (Switzerland), Sanofi (France), Merck & Co. (United States), Serum Institute of India (India), GlaxoSmithKline (United Kingdom), Bio-Manguinhos (Brazil), Biomed Pvt. Ltd (India) and Baxter International, Inc (United States) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Meningococcal Vaccines market by Type (Polysaccharide Vaccines, Conjugate Vaccines, Combination Vaccines and Others), Application (Pneumonia, Meningitis, Bacteremia and Others (Arthritis, Conjunctivitis, Urethritis)) and Region.



On the basis of geography, the market of Meningococcal Vaccines has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Brand, the sub-segment i.e. Menactra will boost the Meningococcal Vaccines market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Pharmacies will boost the Meningococcal Vaccines market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Age, the sub-segment i.e. Infants will boost the Meningococcal Vaccines market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increase in Public-Private Partnerships to Support Development of Vaccines at Low Cost

Market Growth Drivers:
Rising Incidence Of Meningitis Disease and Growing Support By Healthcare Services

Challenges:
Lack of Awareness of the Harmful Effects of Meningitis on Toddlers and Young Children

Restraints:
High Cost Associated With Storage And Supply Of Vaccines

Opportunities:
Increasing Immunization Programs And Government Initiatives and Rising R&D In Meningococcal Vaccines

Market Leaders and their expansionary development strategies
In June 2022, Pfizer Inc., announced that it has entered into an agreement with GlaxoSmithKline (GSK) to acquire its quadrivalent meningitis ACWY vaccines, Nimenrix and Mencevax, for a total consideration of approximately USD 130 million (€115 million).
In September 2022, Pfizer Inc. announced positive top-line results from the pivotal Phase 3 trial (NCT04440163) assessing the safety, tolerability, and immunogenicity of its investigational pentavalent meningococcal vaccine (MenABCWY) in healthy individuals 10 through 25 years of age.


Key Target Audience
Meningococcal Vaccines Manufacturers, Meningococcal Vaccines Suppliers, Raw Material Suppliers, Research and Development Organization, Potential Investors and Government Agencies

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Polysaccharide Vaccines
  • Conjugate Vaccines
  • Combination Vaccines
  • Others
By Application
  • Pneumonia
  • Meningitis
  • Bacteremia
  • Others (Arthritis, Conjunctivitis, Urethritis)
By Brand
  • Menactra
  • Menveo
  • Nimenrix
  • Trumenba
  • Bexsero
  • Others

By Distribution Channel
  • Pharmacies
  • Community Clinics
  • Public Health Agencies
  • Others (hospital pharmacy, private market etc.)

By Age
  • Infants
  • Children
  • Adolescents & Young Adults
  • Adults

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Incidence Of Meningitis Disease
      • 3.2.2. Growing Support By Healthcare Services
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness of the Harmful Effects of Meningitis on Toddlers and Young Children
    • 3.4. Market Trends
      • 3.4.1. Increase in Public-Private Partnerships to Support Development of Vaccines at Low Cost
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Meningococcal Vaccines, by Type, Application, Brand, Distribution Channel, Age and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Meningococcal Vaccines (Value)
      • 5.2.1. Global Meningococcal Vaccines by: Type (Value)
        • 5.2.1.1. Polysaccharide Vaccines
        • 5.2.1.2. Conjugate Vaccines
        • 5.2.1.3. Combination Vaccines
        • 5.2.1.4. Others
      • 5.2.2. Global Meningococcal Vaccines by: Application (Value)
        • 5.2.2.1. Pneumonia
        • 5.2.2.2. Meningitis
        • 5.2.2.3. Bacteremia
        • 5.2.2.4. Others (Arthritis, Conjunctivitis, Urethritis)
      • 5.2.3. Global Meningococcal Vaccines by: Brand (Value)
        • 5.2.3.1. Menactra
        • 5.2.3.2. Menveo
        • 5.2.3.3. Nimenrix
        • 5.2.3.4. Trumenba
        • 5.2.3.5. Bexsero
        • 5.2.3.6. Others
      • 5.2.4. Global Meningococcal Vaccines by: Distribution Channel (Value)
        • 5.2.4.1. Pharmacies
        • 5.2.4.2. Community Clinics
        • 5.2.4.3. Public Health Agencies
        • 5.2.4.4. Others (hospital pharmacy, private market etc.)
      • 5.2.5. Global Meningococcal Vaccines by: Age (Value)
        • 5.2.5.1. Infants
        • 5.2.5.2. Children
        • 5.2.5.3. Adolescents & Young Adults
        • 5.2.5.4. Adults
      • 5.2.6. Global Meningococcal Vaccines Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Meningococcal Vaccines (Price)
      • 5.3.1. Global Meningococcal Vaccines by: Type (Price)
  • 6. Meningococcal Vaccines: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sanofi (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Merck & Co. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Serum Institute of India (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. GlaxoSmithKline (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Bio-Manguinhos (Brazil)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Biomed Pvt. Ltd (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Baxter International, Inc (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Meningococcal Vaccines Sale, by Type, Application, Brand, Distribution Channel, Age and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Meningococcal Vaccines (Value)
      • 7.2.1. Global Meningococcal Vaccines by: Type (Value)
        • 7.2.1.1. Polysaccharide Vaccines
        • 7.2.1.2. Conjugate Vaccines
        • 7.2.1.3. Combination Vaccines
        • 7.2.1.4. Others
      • 7.2.2. Global Meningococcal Vaccines by: Application (Value)
        • 7.2.2.1. Pneumonia
        • 7.2.2.2. Meningitis
        • 7.2.2.3. Bacteremia
        • 7.2.2.4. Others (Arthritis, Conjunctivitis, Urethritis)
      • 7.2.3. Global Meningococcal Vaccines by: Brand (Value)
        • 7.2.3.1. Menactra
        • 7.2.3.2. Menveo
        • 7.2.3.3. Nimenrix
        • 7.2.3.4. Trumenba
        • 7.2.3.5. Bexsero
        • 7.2.3.6. Others
      • 7.2.4. Global Meningococcal Vaccines by: Distribution Channel (Value)
        • 7.2.4.1. Pharmacies
        • 7.2.4.2. Community Clinics
        • 7.2.4.3. Public Health Agencies
        • 7.2.4.4. Others (hospital pharmacy, private market etc.)
      • 7.2.5. Global Meningococcal Vaccines by: Age (Value)
        • 7.2.5.1. Infants
        • 7.2.5.2. Children
        • 7.2.5.3. Adolescents & Young Adults
        • 7.2.5.4. Adults
      • 7.2.6. Global Meningococcal Vaccines Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Meningococcal Vaccines (Price)
      • 7.3.1. Global Meningococcal Vaccines by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Meningococcal Vaccines: by Type(USD Million)
  • Table 2. Meningococcal Vaccines Polysaccharide Vaccines , by Region USD Million (2018-2023)
  • Table 3. Meningococcal Vaccines Conjugate Vaccines , by Region USD Million (2018-2023)
  • Table 4. Meningococcal Vaccines Combination Vaccines , by Region USD Million (2018-2023)
  • Table 5. Meningococcal Vaccines Others , by Region USD Million (2018-2023)
  • Table 6. Meningococcal Vaccines: by Application(USD Million)
  • Table 7. Meningococcal Vaccines Pneumonia , by Region USD Million (2018-2023)
  • Table 8. Meningococcal Vaccines Meningitis , by Region USD Million (2018-2023)
  • Table 9. Meningococcal Vaccines Bacteremia , by Region USD Million (2018-2023)
  • Table 10. Meningococcal Vaccines Others (Arthritis, Conjunctivitis, Urethritis) , by Region USD Million (2018-2023)
  • Table 11. Meningococcal Vaccines: by Brand(USD Million)
  • Table 12. Meningococcal Vaccines Menactra , by Region USD Million (2018-2023)
  • Table 13. Meningococcal Vaccines Menveo , by Region USD Million (2018-2023)
  • Table 14. Meningococcal Vaccines Nimenrix , by Region USD Million (2018-2023)
  • Table 15. Meningococcal Vaccines Trumenba , by Region USD Million (2018-2023)
  • Table 16. Meningococcal Vaccines Bexsero , by Region USD Million (2018-2023)
  • Table 17. Meningococcal Vaccines Others , by Region USD Million (2018-2023)
  • Table 18. Meningococcal Vaccines: by Distribution Channel(USD Million)
  • Table 19. Meningococcal Vaccines Pharmacies , by Region USD Million (2018-2023)
  • Table 20. Meningococcal Vaccines Community Clinics , by Region USD Million (2018-2023)
  • Table 21. Meningococcal Vaccines Public Health Agencies , by Region USD Million (2018-2023)
  • Table 22. Meningococcal Vaccines Others (hospital pharmacy, private market etc.) , by Region USD Million (2018-2023)
  • Table 23. Meningococcal Vaccines: by Age(USD Million)
  • Table 24. Meningococcal Vaccines Infants , by Region USD Million (2018-2023)
  • Table 25. Meningococcal Vaccines Children , by Region USD Million (2018-2023)
  • Table 26. Meningococcal Vaccines Adolescents & Young Adults , by Region USD Million (2018-2023)
  • Table 27. Meningococcal Vaccines Adults , by Region USD Million (2018-2023)
  • Table 28. South America Meningococcal Vaccines, by Country USD Million (2018-2023)
  • Table 29. South America Meningococcal Vaccines, by Type USD Million (2018-2023)
  • Table 30. South America Meningococcal Vaccines, by Application USD Million (2018-2023)
  • Table 31. South America Meningococcal Vaccines, by Brand USD Million (2018-2023)
  • Table 32. South America Meningococcal Vaccines, by Distribution Channel USD Million (2018-2023)
  • Table 33. South America Meningococcal Vaccines, by Age USD Million (2018-2023)
  • Table 34. Brazil Meningococcal Vaccines, by Type USD Million (2018-2023)
  • Table 35. Brazil Meningococcal Vaccines, by Application USD Million (2018-2023)
  • Table 36. Brazil Meningococcal Vaccines, by Brand USD Million (2018-2023)
  • Table 37. Brazil Meningococcal Vaccines, by Distribution Channel USD Million (2018-2023)
  • Table 38. Brazil Meningococcal Vaccines, by Age USD Million (2018-2023)
  • Table 39. Argentina Meningococcal Vaccines, by Type USD Million (2018-2023)
  • Table 40. Argentina Meningococcal Vaccines, by Application USD Million (2018-2023)
  • Table 41. Argentina Meningococcal Vaccines, by Brand USD Million (2018-2023)
  • Table 42. Argentina Meningococcal Vaccines, by Distribution Channel USD Million (2018-2023)
  • Table 43. Argentina Meningococcal Vaccines, by Age USD Million (2018-2023)
  • Table 44. Rest of South America Meningococcal Vaccines, by Type USD Million (2018-2023)
  • Table 45. Rest of South America Meningococcal Vaccines, by Application USD Million (2018-2023)
  • Table 46. Rest of South America Meningococcal Vaccines, by Brand USD Million (2018-2023)
  • Table 47. Rest of South America Meningococcal Vaccines, by Distribution Channel USD Million (2018-2023)
  • Table 48. Rest of South America Meningococcal Vaccines, by Age USD Million (2018-2023)
  • Table 49. Asia Pacific Meningococcal Vaccines, by Country USD Million (2018-2023)
  • Table 50. Asia Pacific Meningococcal Vaccines, by Type USD Million (2018-2023)
  • Table 51. Asia Pacific Meningococcal Vaccines, by Application USD Million (2018-2023)
  • Table 52. Asia Pacific Meningococcal Vaccines, by Brand USD Million (2018-2023)
  • Table 53. Asia Pacific Meningococcal Vaccines, by Distribution Channel USD Million (2018-2023)
  • Table 54. Asia Pacific Meningococcal Vaccines, by Age USD Million (2018-2023)
  • Table 55. China Meningococcal Vaccines, by Type USD Million (2018-2023)
  • Table 56. China Meningococcal Vaccines, by Application USD Million (2018-2023)
  • Table 57. China Meningococcal Vaccines, by Brand USD Million (2018-2023)
  • Table 58. China Meningococcal Vaccines, by Distribution Channel USD Million (2018-2023)
  • Table 59. China Meningococcal Vaccines, by Age USD Million (2018-2023)
  • Table 60. Japan Meningococcal Vaccines, by Type USD Million (2018-2023)
  • Table 61. Japan Meningococcal Vaccines, by Application USD Million (2018-2023)
  • Table 62. Japan Meningococcal Vaccines, by Brand USD Million (2018-2023)
  • Table 63. Japan Meningococcal Vaccines, by Distribution Channel USD Million (2018-2023)
  • Table 64. Japan Meningococcal Vaccines, by Age USD Million (2018-2023)
  • Table 65. India Meningococcal Vaccines, by Type USD Million (2018-2023)
  • Table 66. India Meningococcal Vaccines, by Application USD Million (2018-2023)
  • Table 67. India Meningococcal Vaccines, by Brand USD Million (2018-2023)
  • Table 68. India Meningococcal Vaccines, by Distribution Channel USD Million (2018-2023)
  • Table 69. India Meningococcal Vaccines, by Age USD Million (2018-2023)
  • Table 70. South Korea Meningococcal Vaccines, by Type USD Million (2018-2023)
  • Table 71. South Korea Meningococcal Vaccines, by Application USD Million (2018-2023)
  • Table 72. South Korea Meningococcal Vaccines, by Brand USD Million (2018-2023)
  • Table 73. South Korea Meningococcal Vaccines, by Distribution Channel USD Million (2018-2023)
  • Table 74. South Korea Meningococcal Vaccines, by Age USD Million (2018-2023)
  • Table 75. Taiwan Meningococcal Vaccines, by Type USD Million (2018-2023)
  • Table 76. Taiwan Meningococcal Vaccines, by Application USD Million (2018-2023)
  • Table 77. Taiwan Meningococcal Vaccines, by Brand USD Million (2018-2023)
  • Table 78. Taiwan Meningococcal Vaccines, by Distribution Channel USD Million (2018-2023)
  • Table 79. Taiwan Meningococcal Vaccines, by Age USD Million (2018-2023)
  • Table 80. Australia Meningococcal Vaccines, by Type USD Million (2018-2023)
  • Table 81. Australia Meningococcal Vaccines, by Application USD Million (2018-2023)
  • Table 82. Australia Meningococcal Vaccines, by Brand USD Million (2018-2023)
  • Table 83. Australia Meningococcal Vaccines, by Distribution Channel USD Million (2018-2023)
  • Table 84. Australia Meningococcal Vaccines, by Age USD Million (2018-2023)
  • Table 85. Rest of Asia-Pacific Meningococcal Vaccines, by Type USD Million (2018-2023)
  • Table 86. Rest of Asia-Pacific Meningococcal Vaccines, by Application USD Million (2018-2023)
  • Table 87. Rest of Asia-Pacific Meningococcal Vaccines, by Brand USD Million (2018-2023)
  • Table 88. Rest of Asia-Pacific Meningococcal Vaccines, by Distribution Channel USD Million (2018-2023)
  • Table 89. Rest of Asia-Pacific Meningococcal Vaccines, by Age USD Million (2018-2023)
  • Table 90. Europe Meningococcal Vaccines, by Country USD Million (2018-2023)
  • Table 91. Europe Meningococcal Vaccines, by Type USD Million (2018-2023)
  • Table 92. Europe Meningococcal Vaccines, by Application USD Million (2018-2023)
  • Table 93. Europe Meningococcal Vaccines, by Brand USD Million (2018-2023)
  • Table 94. Europe Meningococcal Vaccines, by Distribution Channel USD Million (2018-2023)
  • Table 95. Europe Meningococcal Vaccines, by Age USD Million (2018-2023)
  • Table 96. Germany Meningococcal Vaccines, by Type USD Million (2018-2023)
  • Table 97. Germany Meningococcal Vaccines, by Application USD Million (2018-2023)
  • Table 98. Germany Meningococcal Vaccines, by Brand USD Million (2018-2023)
  • Table 99. Germany Meningococcal Vaccines, by Distribution Channel USD Million (2018-2023)
  • Table 100. Germany Meningococcal Vaccines, by Age USD Million (2018-2023)
  • Table 101. France Meningococcal Vaccines, by Type USD Million (2018-2023)
  • Table 102. France Meningococcal Vaccines, by Application USD Million (2018-2023)
  • Table 103. France Meningococcal Vaccines, by Brand USD Million (2018-2023)
  • Table 104. France Meningococcal Vaccines, by Distribution Channel USD Million (2018-2023)
  • Table 105. France Meningococcal Vaccines, by Age USD Million (2018-2023)
  • Table 106. Italy Meningococcal Vaccines, by Type USD Million (2018-2023)
  • Table 107. Italy Meningococcal Vaccines, by Application USD Million (2018-2023)
  • Table 108. Italy Meningococcal Vaccines, by Brand USD Million (2018-2023)
  • Table 109. Italy Meningococcal Vaccines, by Distribution Channel USD Million (2018-2023)
  • Table 110. Italy Meningococcal Vaccines, by Age USD Million (2018-2023)
  • Table 111. United Kingdom Meningococcal Vaccines, by Type USD Million (2018-2023)
  • Table 112. United Kingdom Meningococcal Vaccines, by Application USD Million (2018-2023)
  • Table 113. United Kingdom Meningococcal Vaccines, by Brand USD Million (2018-2023)
  • Table 114. United Kingdom Meningococcal Vaccines, by Distribution Channel USD Million (2018-2023)
  • Table 115. United Kingdom Meningococcal Vaccines, by Age USD Million (2018-2023)
  • Table 116. Netherlands Meningococcal Vaccines, by Type USD Million (2018-2023)
  • Table 117. Netherlands Meningococcal Vaccines, by Application USD Million (2018-2023)
  • Table 118. Netherlands Meningococcal Vaccines, by Brand USD Million (2018-2023)
  • Table 119. Netherlands Meningococcal Vaccines, by Distribution Channel USD Million (2018-2023)
  • Table 120. Netherlands Meningococcal Vaccines, by Age USD Million (2018-2023)
  • Table 121. Rest of Europe Meningococcal Vaccines, by Type USD Million (2018-2023)
  • Table 122. Rest of Europe Meningococcal Vaccines, by Application USD Million (2018-2023)
  • Table 123. Rest of Europe Meningococcal Vaccines, by Brand USD Million (2018-2023)
  • Table 124. Rest of Europe Meningococcal Vaccines, by Distribution Channel USD Million (2018-2023)
  • Table 125. Rest of Europe Meningococcal Vaccines, by Age USD Million (2018-2023)
  • Table 126. MEA Meningococcal Vaccines, by Country USD Million (2018-2023)
  • Table 127. MEA Meningococcal Vaccines, by Type USD Million (2018-2023)
  • Table 128. MEA Meningococcal Vaccines, by Application USD Million (2018-2023)
  • Table 129. MEA Meningococcal Vaccines, by Brand USD Million (2018-2023)
  • Table 130. MEA Meningococcal Vaccines, by Distribution Channel USD Million (2018-2023)
  • Table 131. MEA Meningococcal Vaccines, by Age USD Million (2018-2023)
  • Table 132. Middle East Meningococcal Vaccines, by Type USD Million (2018-2023)
  • Table 133. Middle East Meningococcal Vaccines, by Application USD Million (2018-2023)
  • Table 134. Middle East Meningococcal Vaccines, by Brand USD Million (2018-2023)
  • Table 135. Middle East Meningococcal Vaccines, by Distribution Channel USD Million (2018-2023)
  • Table 136. Middle East Meningococcal Vaccines, by Age USD Million (2018-2023)
  • Table 137. Africa Meningococcal Vaccines, by Type USD Million (2018-2023)
  • Table 138. Africa Meningococcal Vaccines, by Application USD Million (2018-2023)
  • Table 139. Africa Meningococcal Vaccines, by Brand USD Million (2018-2023)
  • Table 140. Africa Meningococcal Vaccines, by Distribution Channel USD Million (2018-2023)
  • Table 141. Africa Meningococcal Vaccines, by Age USD Million (2018-2023)
  • Table 142. North America Meningococcal Vaccines, by Country USD Million (2018-2023)
  • Table 143. North America Meningococcal Vaccines, by Type USD Million (2018-2023)
  • Table 144. North America Meningococcal Vaccines, by Application USD Million (2018-2023)
  • Table 145. North America Meningococcal Vaccines, by Brand USD Million (2018-2023)
  • Table 146. North America Meningococcal Vaccines, by Distribution Channel USD Million (2018-2023)
  • Table 147. North America Meningococcal Vaccines, by Age USD Million (2018-2023)
  • Table 148. United States Meningococcal Vaccines, by Type USD Million (2018-2023)
  • Table 149. United States Meningococcal Vaccines, by Application USD Million (2018-2023)
  • Table 150. United States Meningococcal Vaccines, by Brand USD Million (2018-2023)
  • Table 151. United States Meningococcal Vaccines, by Distribution Channel USD Million (2018-2023)
  • Table 152. United States Meningococcal Vaccines, by Age USD Million (2018-2023)
  • Table 153. Canada Meningococcal Vaccines, by Type USD Million (2018-2023)
  • Table 154. Canada Meningococcal Vaccines, by Application USD Million (2018-2023)
  • Table 155. Canada Meningococcal Vaccines, by Brand USD Million (2018-2023)
  • Table 156. Canada Meningococcal Vaccines, by Distribution Channel USD Million (2018-2023)
  • Table 157. Canada Meningococcal Vaccines, by Age USD Million (2018-2023)
  • Table 158. Mexico Meningococcal Vaccines, by Type USD Million (2018-2023)
  • Table 159. Mexico Meningococcal Vaccines, by Application USD Million (2018-2023)
  • Table 160. Mexico Meningococcal Vaccines, by Brand USD Million (2018-2023)
  • Table 161. Mexico Meningococcal Vaccines, by Distribution Channel USD Million (2018-2023)
  • Table 162. Mexico Meningococcal Vaccines, by Age USD Million (2018-2023)
  • Table 163. Meningococcal Vaccines: by Type(USD/Units)
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Company Basic Information, Sales Area and Its Competitors
  • Table 169. Company Basic Information, Sales Area and Its Competitors
  • Table 170. Company Basic Information, Sales Area and Its Competitors
  • Table 171. Company Basic Information, Sales Area and Its Competitors
  • Table 172. Company Basic Information, Sales Area and Its Competitors
  • Table 173. Meningococcal Vaccines: by Type(USD Million)
  • Table 174. Meningococcal Vaccines Polysaccharide Vaccines , by Region USD Million (2025-2030)
  • Table 175. Meningococcal Vaccines Conjugate Vaccines , by Region USD Million (2025-2030)
  • Table 176. Meningococcal Vaccines Combination Vaccines , by Region USD Million (2025-2030)
  • Table 177. Meningococcal Vaccines Others , by Region USD Million (2025-2030)
  • Table 178. Meningococcal Vaccines: by Application(USD Million)
  • Table 179. Meningococcal Vaccines Pneumonia , by Region USD Million (2025-2030)
  • Table 180. Meningococcal Vaccines Meningitis , by Region USD Million (2025-2030)
  • Table 181. Meningococcal Vaccines Bacteremia , by Region USD Million (2025-2030)
  • Table 182. Meningococcal Vaccines Others (Arthritis, Conjunctivitis, Urethritis) , by Region USD Million (2025-2030)
  • Table 183. Meningococcal Vaccines: by Brand(USD Million)
  • Table 184. Meningococcal Vaccines Menactra , by Region USD Million (2025-2030)
  • Table 185. Meningococcal Vaccines Menveo , by Region USD Million (2025-2030)
  • Table 186. Meningococcal Vaccines Nimenrix , by Region USD Million (2025-2030)
  • Table 187. Meningococcal Vaccines Trumenba , by Region USD Million (2025-2030)
  • Table 188. Meningococcal Vaccines Bexsero , by Region USD Million (2025-2030)
  • Table 189. Meningococcal Vaccines Others , by Region USD Million (2025-2030)
  • Table 190. Meningococcal Vaccines: by Distribution Channel(USD Million)
  • Table 191. Meningococcal Vaccines Pharmacies , by Region USD Million (2025-2030)
  • Table 192. Meningococcal Vaccines Community Clinics , by Region USD Million (2025-2030)
  • Table 193. Meningococcal Vaccines Public Health Agencies , by Region USD Million (2025-2030)
  • Table 194. Meningococcal Vaccines Others (hospital pharmacy, private market etc.) , by Region USD Million (2025-2030)
  • Table 195. Meningococcal Vaccines: by Age(USD Million)
  • Table 196. Meningococcal Vaccines Infants , by Region USD Million (2025-2030)
  • Table 197. Meningococcal Vaccines Children , by Region USD Million (2025-2030)
  • Table 198. Meningococcal Vaccines Adolescents & Young Adults , by Region USD Million (2025-2030)
  • Table 199. Meningococcal Vaccines Adults , by Region USD Million (2025-2030)
  • Table 200. South America Meningococcal Vaccines, by Country USD Million (2025-2030)
  • Table 201. South America Meningococcal Vaccines, by Type USD Million (2025-2030)
  • Table 202. South America Meningococcal Vaccines, by Application USD Million (2025-2030)
  • Table 203. South America Meningococcal Vaccines, by Brand USD Million (2025-2030)
  • Table 204. South America Meningococcal Vaccines, by Distribution Channel USD Million (2025-2030)
  • Table 205. South America Meningococcal Vaccines, by Age USD Million (2025-2030)
  • Table 206. Brazil Meningococcal Vaccines, by Type USD Million (2025-2030)
  • Table 207. Brazil Meningococcal Vaccines, by Application USD Million (2025-2030)
  • Table 208. Brazil Meningococcal Vaccines, by Brand USD Million (2025-2030)
  • Table 209. Brazil Meningococcal Vaccines, by Distribution Channel USD Million (2025-2030)
  • Table 210. Brazil Meningococcal Vaccines, by Age USD Million (2025-2030)
  • Table 211. Argentina Meningococcal Vaccines, by Type USD Million (2025-2030)
  • Table 212. Argentina Meningococcal Vaccines, by Application USD Million (2025-2030)
  • Table 213. Argentina Meningococcal Vaccines, by Brand USD Million (2025-2030)
  • Table 214. Argentina Meningococcal Vaccines, by Distribution Channel USD Million (2025-2030)
  • Table 215. Argentina Meningococcal Vaccines, by Age USD Million (2025-2030)
  • Table 216. Rest of South America Meningococcal Vaccines, by Type USD Million (2025-2030)
  • Table 217. Rest of South America Meningococcal Vaccines, by Application USD Million (2025-2030)
  • Table 218. Rest of South America Meningococcal Vaccines, by Brand USD Million (2025-2030)
  • Table 219. Rest of South America Meningococcal Vaccines, by Distribution Channel USD Million (2025-2030)
  • Table 220. Rest of South America Meningococcal Vaccines, by Age USD Million (2025-2030)
  • Table 221. Asia Pacific Meningococcal Vaccines, by Country USD Million (2025-2030)
  • Table 222. Asia Pacific Meningococcal Vaccines, by Type USD Million (2025-2030)
  • Table 223. Asia Pacific Meningococcal Vaccines, by Application USD Million (2025-2030)
  • Table 224. Asia Pacific Meningococcal Vaccines, by Brand USD Million (2025-2030)
  • Table 225. Asia Pacific Meningococcal Vaccines, by Distribution Channel USD Million (2025-2030)
  • Table 226. Asia Pacific Meningococcal Vaccines, by Age USD Million (2025-2030)
  • Table 227. China Meningococcal Vaccines, by Type USD Million (2025-2030)
  • Table 228. China Meningococcal Vaccines, by Application USD Million (2025-2030)
  • Table 229. China Meningococcal Vaccines, by Brand USD Million (2025-2030)
  • Table 230. China Meningococcal Vaccines, by Distribution Channel USD Million (2025-2030)
  • Table 231. China Meningococcal Vaccines, by Age USD Million (2025-2030)
  • Table 232. Japan Meningococcal Vaccines, by Type USD Million (2025-2030)
  • Table 233. Japan Meningococcal Vaccines, by Application USD Million (2025-2030)
  • Table 234. Japan Meningococcal Vaccines, by Brand USD Million (2025-2030)
  • Table 235. Japan Meningococcal Vaccines, by Distribution Channel USD Million (2025-2030)
  • Table 236. Japan Meningococcal Vaccines, by Age USD Million (2025-2030)
  • Table 237. India Meningococcal Vaccines, by Type USD Million (2025-2030)
  • Table 238. India Meningococcal Vaccines, by Application USD Million (2025-2030)
  • Table 239. India Meningococcal Vaccines, by Brand USD Million (2025-2030)
  • Table 240. India Meningococcal Vaccines, by Distribution Channel USD Million (2025-2030)
  • Table 241. India Meningococcal Vaccines, by Age USD Million (2025-2030)
  • Table 242. South Korea Meningococcal Vaccines, by Type USD Million (2025-2030)
  • Table 243. South Korea Meningococcal Vaccines, by Application USD Million (2025-2030)
  • Table 244. South Korea Meningococcal Vaccines, by Brand USD Million (2025-2030)
  • Table 245. South Korea Meningococcal Vaccines, by Distribution Channel USD Million (2025-2030)
  • Table 246. South Korea Meningococcal Vaccines, by Age USD Million (2025-2030)
  • Table 247. Taiwan Meningococcal Vaccines, by Type USD Million (2025-2030)
  • Table 248. Taiwan Meningococcal Vaccines, by Application USD Million (2025-2030)
  • Table 249. Taiwan Meningococcal Vaccines, by Brand USD Million (2025-2030)
  • Table 250. Taiwan Meningococcal Vaccines, by Distribution Channel USD Million (2025-2030)
  • Table 251. Taiwan Meningococcal Vaccines, by Age USD Million (2025-2030)
  • Table 252. Australia Meningococcal Vaccines, by Type USD Million (2025-2030)
  • Table 253. Australia Meningococcal Vaccines, by Application USD Million (2025-2030)
  • Table 254. Australia Meningococcal Vaccines, by Brand USD Million (2025-2030)
  • Table 255. Australia Meningococcal Vaccines, by Distribution Channel USD Million (2025-2030)
  • Table 256. Australia Meningococcal Vaccines, by Age USD Million (2025-2030)
  • Table 257. Rest of Asia-Pacific Meningococcal Vaccines, by Type USD Million (2025-2030)
  • Table 258. Rest of Asia-Pacific Meningococcal Vaccines, by Application USD Million (2025-2030)
  • Table 259. Rest of Asia-Pacific Meningococcal Vaccines, by Brand USD Million (2025-2030)
  • Table 260. Rest of Asia-Pacific Meningococcal Vaccines, by Distribution Channel USD Million (2025-2030)
  • Table 261. Rest of Asia-Pacific Meningococcal Vaccines, by Age USD Million (2025-2030)
  • Table 262. Europe Meningococcal Vaccines, by Country USD Million (2025-2030)
  • Table 263. Europe Meningococcal Vaccines, by Type USD Million (2025-2030)
  • Table 264. Europe Meningococcal Vaccines, by Application USD Million (2025-2030)
  • Table 265. Europe Meningococcal Vaccines, by Brand USD Million (2025-2030)
  • Table 266. Europe Meningococcal Vaccines, by Distribution Channel USD Million (2025-2030)
  • Table 267. Europe Meningococcal Vaccines, by Age USD Million (2025-2030)
  • Table 268. Germany Meningococcal Vaccines, by Type USD Million (2025-2030)
  • Table 269. Germany Meningococcal Vaccines, by Application USD Million (2025-2030)
  • Table 270. Germany Meningococcal Vaccines, by Brand USD Million (2025-2030)
  • Table 271. Germany Meningococcal Vaccines, by Distribution Channel USD Million (2025-2030)
  • Table 272. Germany Meningococcal Vaccines, by Age USD Million (2025-2030)
  • Table 273. France Meningococcal Vaccines, by Type USD Million (2025-2030)
  • Table 274. France Meningococcal Vaccines, by Application USD Million (2025-2030)
  • Table 275. France Meningococcal Vaccines, by Brand USD Million (2025-2030)
  • Table 276. France Meningococcal Vaccines, by Distribution Channel USD Million (2025-2030)
  • Table 277. France Meningococcal Vaccines, by Age USD Million (2025-2030)
  • Table 278. Italy Meningococcal Vaccines, by Type USD Million (2025-2030)
  • Table 279. Italy Meningococcal Vaccines, by Application USD Million (2025-2030)
  • Table 280. Italy Meningococcal Vaccines, by Brand USD Million (2025-2030)
  • Table 281. Italy Meningococcal Vaccines, by Distribution Channel USD Million (2025-2030)
  • Table 282. Italy Meningococcal Vaccines, by Age USD Million (2025-2030)
  • Table 283. United Kingdom Meningococcal Vaccines, by Type USD Million (2025-2030)
  • Table 284. United Kingdom Meningococcal Vaccines, by Application USD Million (2025-2030)
  • Table 285. United Kingdom Meningococcal Vaccines, by Brand USD Million (2025-2030)
  • Table 286. United Kingdom Meningococcal Vaccines, by Distribution Channel USD Million (2025-2030)
  • Table 287. United Kingdom Meningococcal Vaccines, by Age USD Million (2025-2030)
  • Table 288. Netherlands Meningococcal Vaccines, by Type USD Million (2025-2030)
  • Table 289. Netherlands Meningococcal Vaccines, by Application USD Million (2025-2030)
  • Table 290. Netherlands Meningococcal Vaccines, by Brand USD Million (2025-2030)
  • Table 291. Netherlands Meningococcal Vaccines, by Distribution Channel USD Million (2025-2030)
  • Table 292. Netherlands Meningococcal Vaccines, by Age USD Million (2025-2030)
  • Table 293. Rest of Europe Meningococcal Vaccines, by Type USD Million (2025-2030)
  • Table 294. Rest of Europe Meningococcal Vaccines, by Application USD Million (2025-2030)
  • Table 295. Rest of Europe Meningococcal Vaccines, by Brand USD Million (2025-2030)
  • Table 296. Rest of Europe Meningococcal Vaccines, by Distribution Channel USD Million (2025-2030)
  • Table 297. Rest of Europe Meningococcal Vaccines, by Age USD Million (2025-2030)
  • Table 298. MEA Meningococcal Vaccines, by Country USD Million (2025-2030)
  • Table 299. MEA Meningococcal Vaccines, by Type USD Million (2025-2030)
  • Table 300. MEA Meningococcal Vaccines, by Application USD Million (2025-2030)
  • Table 301. MEA Meningococcal Vaccines, by Brand USD Million (2025-2030)
  • Table 302. MEA Meningococcal Vaccines, by Distribution Channel USD Million (2025-2030)
  • Table 303. MEA Meningococcal Vaccines, by Age USD Million (2025-2030)
  • Table 304. Middle East Meningococcal Vaccines, by Type USD Million (2025-2030)
  • Table 305. Middle East Meningococcal Vaccines, by Application USD Million (2025-2030)
  • Table 306. Middle East Meningococcal Vaccines, by Brand USD Million (2025-2030)
  • Table 307. Middle East Meningococcal Vaccines, by Distribution Channel USD Million (2025-2030)
  • Table 308. Middle East Meningococcal Vaccines, by Age USD Million (2025-2030)
  • Table 309. Africa Meningococcal Vaccines, by Type USD Million (2025-2030)
  • Table 310. Africa Meningococcal Vaccines, by Application USD Million (2025-2030)
  • Table 311. Africa Meningococcal Vaccines, by Brand USD Million (2025-2030)
  • Table 312. Africa Meningococcal Vaccines, by Distribution Channel USD Million (2025-2030)
  • Table 313. Africa Meningococcal Vaccines, by Age USD Million (2025-2030)
  • Table 314. North America Meningococcal Vaccines, by Country USD Million (2025-2030)
  • Table 315. North America Meningococcal Vaccines, by Type USD Million (2025-2030)
  • Table 316. North America Meningococcal Vaccines, by Application USD Million (2025-2030)
  • Table 317. North America Meningococcal Vaccines, by Brand USD Million (2025-2030)
  • Table 318. North America Meningococcal Vaccines, by Distribution Channel USD Million (2025-2030)
  • Table 319. North America Meningococcal Vaccines, by Age USD Million (2025-2030)
  • Table 320. United States Meningococcal Vaccines, by Type USD Million (2025-2030)
  • Table 321. United States Meningococcal Vaccines, by Application USD Million (2025-2030)
  • Table 322. United States Meningococcal Vaccines, by Brand USD Million (2025-2030)
  • Table 323. United States Meningococcal Vaccines, by Distribution Channel USD Million (2025-2030)
  • Table 324. United States Meningococcal Vaccines, by Age USD Million (2025-2030)
  • Table 325. Canada Meningococcal Vaccines, by Type USD Million (2025-2030)
  • Table 326. Canada Meningococcal Vaccines, by Application USD Million (2025-2030)
  • Table 327. Canada Meningococcal Vaccines, by Brand USD Million (2025-2030)
  • Table 328. Canada Meningococcal Vaccines, by Distribution Channel USD Million (2025-2030)
  • Table 329. Canada Meningococcal Vaccines, by Age USD Million (2025-2030)
  • Table 330. Mexico Meningococcal Vaccines, by Type USD Million (2025-2030)
  • Table 331. Mexico Meningococcal Vaccines, by Application USD Million (2025-2030)
  • Table 332. Mexico Meningococcal Vaccines, by Brand USD Million (2025-2030)
  • Table 333. Mexico Meningococcal Vaccines, by Distribution Channel USD Million (2025-2030)
  • Table 334. Mexico Meningococcal Vaccines, by Age USD Million (2025-2030)
  • Table 335. Meningococcal Vaccines: by Type(USD/Units)
  • Table 336. Research Programs/Design for This Report
  • Table 337. Key Data Information from Secondary Sources
  • Table 338. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Meningococcal Vaccines: by Type USD Million (2018-2023)
  • Figure 5. Global Meningococcal Vaccines: by Application USD Million (2018-2023)
  • Figure 6. Global Meningococcal Vaccines: by Brand USD Million (2018-2023)
  • Figure 7. Global Meningococcal Vaccines: by Distribution Channel USD Million (2018-2023)
  • Figure 8. Global Meningococcal Vaccines: by Age USD Million (2018-2023)
  • Figure 9. South America Meningococcal Vaccines Share (%), by Country
  • Figure 10. Asia Pacific Meningococcal Vaccines Share (%), by Country
  • Figure 11. Europe Meningococcal Vaccines Share (%), by Country
  • Figure 12. MEA Meningococcal Vaccines Share (%), by Country
  • Figure 13. North America Meningococcal Vaccines Share (%), by Country
  • Figure 14. Global Meningococcal Vaccines: by Type USD/Units (2018-2023)
  • Figure 15. Global Meningococcal Vaccines share by Players 2023 (%)
  • Figure 16. Global Meningococcal Vaccines share by Players (Top 3) 2023(%)
  • Figure 17. Global Meningococcal Vaccines share by Players (Top 5) 2023(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 21. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 23. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 24. Sanofi (France) Revenue: by Geography 2023
  • Figure 25. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Merck & Co. (United States) Revenue: by Geography 2023
  • Figure 27. Serum Institute of India (India) Revenue, Net Income and Gross profit
  • Figure 28. Serum Institute of India (India) Revenue: by Geography 2023
  • Figure 29. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 30. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2023
  • Figure 31. Bio-Manguinhos (Brazil) Revenue, Net Income and Gross profit
  • Figure 32. Bio-Manguinhos (Brazil) Revenue: by Geography 2023
  • Figure 33. Biomed Pvt. Ltd (India) Revenue, Net Income and Gross profit
  • Figure 34. Biomed Pvt. Ltd (India) Revenue: by Geography 2023
  • Figure 35. Baxter International, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 36. Baxter International, Inc (United States) Revenue: by Geography 2023
  • Figure 37. Global Meningococcal Vaccines: by Type USD Million (2025-2030)
  • Figure 38. Global Meningococcal Vaccines: by Application USD Million (2025-2030)
  • Figure 39. Global Meningococcal Vaccines: by Brand USD Million (2025-2030)
  • Figure 40. Global Meningococcal Vaccines: by Distribution Channel USD Million (2025-2030)
  • Figure 41. Global Meningococcal Vaccines: by Age USD Million (2025-2030)
  • Figure 42. South America Meningococcal Vaccines Share (%), by Country
  • Figure 43. Asia Pacific Meningococcal Vaccines Share (%), by Country
  • Figure 44. Europe Meningococcal Vaccines Share (%), by Country
  • Figure 45. MEA Meningococcal Vaccines Share (%), by Country
  • Figure 46. North America Meningococcal Vaccines Share (%), by Country
  • Figure 47. Global Meningococcal Vaccines: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Pfizer Inc. (United States)
  • Novartis AG (Switzerland)
  • Sanofi (France)
  • Merck & Co. (United States)
  • Serum Institute of India (India)
  • GlaxoSmithKline (United Kingdom)
  • Bio-Manguinhos (Brazil)
  • Biomed Pvt. Ltd (India)
  • Baxter International, Inc (United States)
Select User Access Type

Key Highlights of Report


Apr 2024 203 Pages 65 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Meningococcal Vaccines Quantitative research analysis
Global Meningococcal Vaccines Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Pfizer Inc. (United States), Novartis AG (Switzerland), Sanofi (France), Merck & Co. (United States), Serum Institute of India (India), GlaxoSmithKline (United Kingdom), Bio-Manguinhos (Brazil), Biomed Pvt. Ltd (India) and Baxter International, Inc (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increase in Public-Private Partnerships to Support Development of Vaccines at Low Cost" is seen as one of major influencing trends for Meningococcal Vaccines Market during projected period 2023-2030.
The Meningococcal Vaccines market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Meningococcal Vaccines Report?

Have a Query? Click Here

Other Related Reports

Asthma Treatment Drugs Comprehensive Study by Type (Long-term Control Medications, Quick-relief Medications (Rescue Medications), Medications for Allergy-induced Asthma), Application (Hospital Pharma...
$ 3750
Nevirapine Comprehensive Study by Type (100 mg, 200 mg, 400 mg), Application (Women (Pregnant, Non- pregnant), Men), Method (Antiretroviral Therapy, Hepatotoxicity) Players and Region - Global Market...
$ 3500
Medication Adherence Packaging Systems Comprehensive Study by Type (Unit-dose Packaging Systems, Multi-dose Packaging Systems), Packaging (Ampoules, Vials, Prefilled Syringes & Injectable, Blisters, ...
$ 3750
Osteoarthritis Pain Drugs Comprehensive Study by Type (Oral, Injection, External), Application (Medical Care, Personal Care), Therapies (Non- Pharmacological Therapy, Pharmacological Therapy, Surgica...
$ 3750
Docusate Sodium Comprehensive Study by Type (DSS 100%, DSS 85%, DSS 50%), Application (Exicipient, Active Pharmaceutical Ingredients, Constipation, Pesticide adjuvant, Micelle encapsulation), Route o...
$ 3650
Resistant Maltodextrin Comprehensive Study by Type (Corn-based, Wheat-based, Others), Application (Beverages, Bakery & Confectionery, Dairy Products, Nutraceuticals, Others) Players and Region - Glob...
$ 3500